Edgewise Therapeutics Inc (NASDAQ: EWTX) kicked off on Friday, down -3.49% from the previous trading day, before settling in for the closing price of $14.63. Over the past 52 weeks, EWTX has traded in a range of $10.60-$38.12.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -49.00%. While this was happening, its average annual earnings per share was recorded -20.45%. With a float of $77.09 million, this company’s outstanding shares have now reached $95.21 million.
Considering the fact that the conglomerate employs 110 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Edgewise Therapeutics Inc (EWTX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Edgewise Therapeutics Inc is 26.72%, while institutional ownership is 74.65%. The most recent insider transaction that took place on May 02 ’25, was worth 25,520. In this transaction Chief Scientific Officer of this company sold 1,551 shares at a rate of $16.45, taking the stock ownership to the 18,521 shares. Before that another transaction happened on May 02 ’25, when Company’s General Counsel sold 1,930 for $16.45, making the entire transaction worth $31,757. This insider now owns 6,531 shares in total.
Edgewise Therapeutics Inc (EWTX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -20.45% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.76% during the next five years compared to -49.00% drop over the previous five years of trading.
Edgewise Therapeutics Inc (NASDAQ: EWTX) Trading Performance Indicators
Take a look at Edgewise Therapeutics Inc’s (EWTX) current performance indicators. Last quarter, stock had a quick ratio of 20.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -2.01 in one year’s time.
Technical Analysis of Edgewise Therapeutics Inc (EWTX)
Compared to the last year’s volume of 1.3 million, its volume of 0.53 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 85.14%.
During the past 100 days, Edgewise Therapeutics Inc’s (EWTX) raw stochastic average was set at 18.11%, which indicates a significant decrease from 72.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.59 in the past 14 days, which was lower than the 1.14 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.20, while its 200-day Moving Average is $23.20. Nevertheless, the first resistance level for the watch stands at $14.55 in the near term. At $14.99, the stock is likely to face the second major resistance level. The third major resistance level sits at $15.37. If the price goes on to break the first support level at $13.73, it is likely to go to the next support level at $13.35. Should the price break the second support level, the third support level stands at $12.91.
Edgewise Therapeutics Inc (NASDAQ: EWTX) Key Stats
The company with the Market Capitalisation of 1.49 billion has total of 105,200K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -133,810 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -40,800 K.
